Intellia Therapeutics (NASDAQ:NTLA) Upgraded by StockNews.com to “Sell” Rating

StockNews.com upgraded shares of Intellia Therapeutics (NASDAQ:NTLA) to a sell rating in a report published on Friday.

NTLA has been the topic of several other research reports. The Goldman Sachs Group decreased their target price on Intellia Therapeutics from $31.00 to $20.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. Robert W. Baird decreased their price target on Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. Stifel Nicolaus decreased their target price on Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating on the stock in a research report on Wednesday, September 11th. Evercore ISI raised Intellia Therapeutics to a “strong-buy” rating in a report on Friday, August 9th. Finally, Wedbush reiterated a “neutral” rating and issued a $14.00 target price on shares of Intellia Therapeutics in a research note on Thursday. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $58.00.

Intellia Therapeutics Stock Performance

Shares of Intellia Therapeutics stock opened at $16.73 on Friday. The stock’s fifty day moving average price is $19.17 and its 200-day moving average price is $22.23. Intellia Therapeutics has a 12 month low of $13.95 and a 12 month high of $34.87.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, beating the consensus estimate of ($1.37) by $0.03. The company had revenue of $9.10 million for the quarter, compared to analysts’ expectations of $8.28 million. The firm’s revenue was down 24.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.38) earnings per share. On average, equities research analysts forecast that Intellia Therapeutics will post -5.21 earnings per share for the current year.

Insider Buying and Selling

In related news, CAO Michael P. Dube sold 2,012 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total value of $38,248.12. Following the completion of the transaction, the chief accounting officer now owns 47,012 shares of the company’s stock, valued at $893,698.12. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 3.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Intellia Therapeutics

Several large investors have recently modified their holdings of the business. First Horizon Advisors Inc. raised its stake in shares of Intellia Therapeutics by 22.1% during the second quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock valued at $58,000 after acquiring an additional 472 shares during the last quarter. Elmwood Wealth Management Inc. raised its stake in Intellia Therapeutics by 0.9% during the third quarter. Elmwood Wealth Management Inc. now owns 67,774 shares of the company’s stock worth $1,393,000 after buying an additional 600 shares during the last quarter. Interchange Capital Partners LLC raised its stake in Intellia Therapeutics by 6.5% during the first quarter. Interchange Capital Partners LLC now owns 10,909 shares of the company’s stock worth $303,000 after buying an additional 670 shares during the last quarter. Allspring Global Investments Holdings LLC raised its stake in Intellia Therapeutics by 9.2% during the first quarter. Allspring Global Investments Holdings LLC now owns 8,894 shares of the company’s stock worth $245,000 after buying an additional 750 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in Intellia Therapeutics by 27.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock worth $77,000 after buying an additional 794 shares during the last quarter. Institutional investors own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.